4D Molecular Therapeutics vs Maze Therapeutics
FDMT and MAZE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How FDMT and MAZE compare
Maze Therapeutics is the larger company, worth 2.2 times as much as 4D Molecular Therapeutics ($2.0B against $938M).
4D Molecular Therapeutics scores higher on the StockData Score (7 against 4 for Maze Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | FDMT | MAZE |
|---|---|---|
| Size and price | ||
| Market cap | $938M | $2.0B |
| Share price | $12.99 | $36.73 |
| Change, 1 year | 27.7% | 20.5% |
| Change, 5 years | −43.7% | – |
| Beta (5Y) | 1.35 | 0.90 |
| Employees | 196 | 141 |
| StockData Score | ||
| Total score | 7 (better) | 4 |
| Valuation score | 0 | 0 |
| Growth score | 2 (better) | 0 |
| Performance score | 2 (better) | 1 |
| Health score | 3 | 3 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 10.2× | – |
| P/B | 2.3× (better) | 4.8× |
| FCF yield | – | −5.6% |
| Fair value | $12.76 | – |
| Margin of safety | −1.8% | – |
| Growth | ||
| Revenue growth (TTM) | 278712% | – |
| Revenue growth, 5Y average | 44.3% | – |
| Profitability | ||
| Operating margin | −214% | – |
| Net margin | −195% | – |
| Return on equity | −43.3% | −37.5% (better) |
| Return on invested capital | −161% (better) | −353% |
| Financial health | ||
| Debt / equity | 0.05 (better) | 0.09 |
| Current ratio | 8.03 | 14.14 (better) |
| Altman Z-score | 3.87 | 12.90 (better) |
| Piotroski F-score | 4 (better) | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 80.5% | 105% |
| Held by insiders | 2.1% | 16.9% |
| Insider net buying, 12 months | −$5.3M (better) | −$25.0M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 15.4% | 14.5% |
Go deeper
- FDMT stock overview
- FDMT income statement
- FDMT valuation and score
- MAZE stock overview
- MAZE income statement
- MAZE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.